What does 98.8% purity on a C18 column actually tell me about an ecnoglutide vial?

What I am working with: 98.8% · a C18 column · ecnoglutide.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What would I need in addition before this supported a decision?

It tells you 98.8 per cent of the integrated area came off a C18 column where ecnoglutide comes off, and the remaining 1.2 per cent did not. That is an area statement at one wavelength, not a mass statement about the vial: 1.2 per cent of area is only 1.2 per cent of mass if every impurity absorbs exactly as strongly as the parent, which none of them do. It also says nothing about how many milligrams are in the glass — water, counter-ion and a short fill are all invisible to it. What a C18 column does add is a constraint on what could be hiding: a column that retains by hydrophobicity separates deletion sequences well and separates isomers of identical hydrophobicity not at all.

To be exact about it, method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

Ask for the chromatogram and the system suitability data, not just the number.